Compare ATPC & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATPC | NSRX |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | Malaysia | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.0M | 63.4M |
| IPO Year | N/A | 2025 |
| Metric | ATPC | NSRX |
|---|---|---|
| Price | $1.23 | $6.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | ★ 33.4K | 3.0K |
| Earning Date | 11-13-2025 | 12-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,484,905.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.66 | N/A |
| 52 Week Low | $0.90 | $5.90 |
| 52 Week High | $2.93 | $9.99 |
| Indicator | ATPC | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.59 | N/A |
| Support Level | $1.21 | N/A |
| Resistance Level | $1.38 | N/A |
| Average True Range (ATR) | 0.07 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 18.52 | 0.00 |
Agape ATP Corp through its subsidiaries is engaged in providing health and wellness products and health solution advisory services. The principal activities of the company is to supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system of the human body and various wellness programs. Its segments include: Skin care, health and wellness segment includes the provision of health and wellness products and health solution advisory services; and Green energy segment includes providing renewable energy products, technical solutions, installations and maintenance services. It derives maximum revenue from Skin care, health and wellness segment.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.